Nanoscope Therapeutics Announces PMDA Acceptance and Priority Review of New Drug Application for MOGENRY® in Japan for the Treatment of Inherited Retinal Dystrophies ...Middle East

PR Newswire - News
Nanoscope Therapeutics Announces PMDA Acceptance and Priority Review of New Drug Application for MOGENRY® in Japan for the Treatment of Inherited Retinal Dystrophies

If approved, MOGENRY® would be the first disease-agnostic treatment for patients with inherited retinal dystrophies (IRDs) PMDA has accepted the application and the file will be reviewed on Priority, building on the Sakigake and Orphan drug designations granted to MOGENRY for IRDs in...

    Hence then, the article about nanoscope therapeutics announces pmda acceptance and priority review of new drug application for mogenry in japan for the treatment of inherited retinal dystrophies was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

    Read More Details
    Finally We wish PressBee provided you with enough information of ( Nanoscope Therapeutics Announces PMDA Acceptance and Priority Review of New Drug Application for MOGENRY® in Japan for the Treatment of Inherited Retinal Dystrophies )

    Apple Storegoogle play

    Last updated :

    Also on site :

    Most viewed in News